Zenas BioPharma, Inc. ZBIO
28.19 USD -0.51 (-1.78%)
Nov 12, 2026, 11:48 AM EST
27.42 Day range 28.75
13.50 52-week range 44.60
- YTD
- -22.36%
- 1 year
- -21.26%
- Market cap
- 1.91B
- Revenue (ttm)
- 11.00M
- EPS (ttm)
- -10.08
- Shares out
- 67.82M
- Forward P/E
- -5.95
- YTD return
- -22.36%
- 1-year return
- -21.26%
- Volume
- 155.04K
- Avg volume
- 652.52K
- Open
- 28.18
- Previous close
- 28.70
- Day's range
- 27.42 – 28.75
- 52-week range
- 13.50 – 44.60
- Beta
- -0.86
- Analysts
- Strong Buy
- Price target
- 47.88 (+69.8%)
- Earnings date
- Mar 15, 2027
5D +0.74 (+2.65%)
Key statistics
- Enterprise value
- 1.65B
- PEG ratio
- 0.00
- Price / sales
- 176.94
- Price / book
- 9.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -256.19M
- Total cash
- 585.31M
- Total debt
- 300.89M
- Return on equity
- -265.11%
- Short % of float
- 24.14%
- 50-day average
- 28.85
- 200-day average
- 25.23
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.88 +69.8% upside
Now 28.19
- Target (low)
- 32.00
- Target (mean)
- 47.88
- Target (high)
- 59.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy0
- Buy7
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 15, 2027
Expected Mar 15, 2027. Consensus EPS estimate -1.31.
Financials — quick view
ZBIO Revenue — quarterly 10.00M
ZBIO Net income — quarterly -108.92M
ZBIO EPS — quarterly -1.65
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 15, 2027 | Mar 30, 2027 | -1.36 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.24 | -1.65 | -0.41 | -33.06% |
| Aug 12, 2026 | Jun 30, 2026 | -1.12 | -1.77 | -0.65 | -58.04% |
| May 13, 2026 | Mar 31, 2026 | -1.37 | -1.46 | -0.09 | -6.57% |
| Mar 16, 2026 | Dec 31, 2025 | -1.06 | -4.54 | -3.48 | -328.30% |
| Nov 12, 2025 | Sep 30, 2025 | -0.87 | -1.22 | -0.35 | -40.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 30, 2026 | Citigroup | main | Buy | Buy |
| Sep 30, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 30, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Aug 14, 2026 | Guggenheim | reit | Buy | Buy |
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zenasbio.com
News
Zenas BioPharma, Inc. $ZBIO Shares Acquired by Alps Advisors Inc. 
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference 
Zenas BioPharma Q3 EPS $(1.65) Misses $(1.33) Estimate, Sales $10.000M 
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target - Zenas BioPharma Presents New Obexelimab Data In Immunoglobulin G4-Related Disease At 6th International Symposium On IgG4-Related Disease
Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48 - Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target
- HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026
Your note
Sign in to keep a note on ZBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN PATRICIA L | Director | Purchase | Feb 12, 2026 | 19,860 |
| ENRIGHT PATRICK G. | Director | Purchase | Oct 8, 2025 | 0 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unknown | Purchase | Mar 30, 2026 | 0 |
| FARMER JOSEPH L | President | Stock Award(Grant) | Feb 4, 2026 | 974 |
| FOX JENNIFER A | Chief Financial Officer | Stock Award(Grant) | Feb 4, 2026 | 1,592 |
| LU HONGBO B | Director | Purchase | Mar 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.44% | 9,792,887 | 281.06M | Sep 29, 2026 |
| SR One Capital Management, LP | 7.43% | 5,037,854 | 144.59M | Jun 29, 2026 |
| NEA Management Company, LLC | 5.93% | 4,023,219 | 115.47M | Jun 29, 2026 |
| Enavate Sciences Gp, LLC | 5.78% | 3,919,159 | 112.48M | Jun 29, 2026 |
| Federated Hermes, Inc. | 4.60% | 3,116,805 | 89.45M | Jun 29, 2026 |
| Blackrock Inc. | 3.96% | 2,686,225 | 77.09M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 4.33% | 2,937,055 | 84.29M | Jul 30, 2026 |
| SmallCap World Fund Inc | 4.20% | 2,849,198 | 81.77M | Sep 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 2.69% | 1,822,567 | 52.31M | Jul 30, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 1.85% | 1,252,083 | 35.93M | Jul 30, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.81% | 1,226,799 | 35.21M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.59% | 1,080,000 | 31.00M | Sep 29, 2026 |